Ysios Capital has supplied a series A extension that follows an initial tranche co-led by Kurma Partners and Sunstone Life Science Ventures in November 2020.
Synendos Therapeutics, a Switzerland-based spinout of University of Bern focused on central nervous system disorders, has raised additional series A financing to bring the round’s total to CHF24m ($26.4m).
Ysios Capital supplied the extension after Kurma Partners and Sunstone Life Science Ventures had provided an initial $21.9m tranche in November last year.
Founded in 2019, Synendos is working on inhibitors for a newly identified target in the body’s endocannabinoid system, a key neuromodulator system in the central nervous system. The cash has been allocated to the completion of preclinical development of the spinout’s lead asset.
Prof Jutta Heim has been appointed chairwoman of the board in conjunction with the round.